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The spread of influenza A viruses is partially controlled and prevented by vaccination. 
The matrix protein 2 ectodomain (M2e) is the most conserved sequence in influenza A 
viruses, and is therefore a good potential target for a vaccine to protect against multiple 
virus subtypes. We explored the feasibility of an M2e-based universal influenza A vaccine 
candidate based on the highly pathogenic avian influenza A virus, H5N1. A synthetic 
M2e gene was human- and plant-codon optimized and fused in-frame with a sequence 
encoding the N-terminal proline-rich domain (Zera®) of the γ-zein protein of maize. 
Zera®M2e was expressed transiently in Nicotiana benthamiana and Sf21 baculovirus/
insect cell expression systems, and Zera®M2e protein bodies (PBs) were successfully 
produced in both expression systems. The plant-produced Zera®M2e PBs were purified 
and injected into Balb/c mice. Western blot analysis using insect cell-produced Zera®M2e 
PBs and multiple tandem M2e sequences (5xM2e) fused with the avian influenza H5N1 
transmembrane and cytosolic tail (5xM2e_tHA) confirmed the presence of M2e-specific 
antibodies in immunized mice sera. The immunogenicity of the Zera®M2e indicates that 
our plant-produced protein has potential as an inexpensive universal influenza A vaccine.
Keywords: influenza a virus, M2e, plant expression, insect cell expression, vaccine
inTrODUcTiOn
Influenza A viruses can be highly contagious, causing acute viral respiratory diseases seasonally in 
the human population (Cox and Subbarao, 1999; Thompson et al., 2003). Currently, vaccination 
with selected inactivated influenza virus strains is the most effective way of reducing the morbidity 
and mortality caused by these viruses (Cox and Subbarao, 1999). Influenza A viruses are divided 
into subtypes by their two surface glycoproteins, the hemagglutinin (HA) and neuraminidase (NA). 
HA and NA are the primary targets for vaccine development as they elicit neutralizing immune 
responses (Johansson et al., 1989; Fiore et al., 2009). Unfortunately, due to the high mutation rate of 
these glycoproteins, influenza vaccines need to be manufactured seasonally in order to be effective 
against the current circulating strains (Webster et al., 1992). It would therefore be ideal to develop a 
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universal vaccine that is cross-protective against multiple influ-
enza A virus strains as well as against subtypes (Price et al., 2010; 
Andersson et al., 2012).
There is a type III integral membrane protein (M2) present on 
the surface of the influenza A virus particle (Lamb et al., 1985). 
It functions as a pH-activated ion channel (viroporin) and is 
required for viral infection (Black et al., 1993). It also prevents low 
pH-induced structural changes in HA during maturation (Sugrue 
and Hay, 1991), and thus plays a role in viral assembly (Chen 
et al., 2008; Rossman et al., 2010). M2 (97 amino acids) consists of 
an N-terminal ectodomain (M2e) (23 amino acids), a lipid bilayer 
spanning single transmembrane domain (19 amino acids) and a 
C-terminal cytosolic tail (54 amino acids), and polymerizes into 
homotetramers in the virion envelope (Pinto and Lamb, 2006). 
The M2e sequence is highly conserved in all influenza A viruses 
(Black et al., 1993; Betakova, 2007). It also plays an important role 
in the incorporation into virions (Park et al., 1998), and it can 
elicit antibodies that can neutralize virion infectivity (Fiers et al., 
2004; Feng et al., 2006). Thus, this domain has the potential to 
be used as an influenza A virus universal vaccine. However, M2e 
is covered by the HA and NA proteins in intact virions, and it is 
therefore unable to react effectively with immune effector cells, 
making it poorly immunogenic (Lamb et al., 1985; Jegerlehner 
et al., 2004; Feng et al., 2006). In attempts to enhance its immu-
nogenicity, M2e has been linked to different carrier molecules, 
such as the TLR5 ligand flagellin (Huleatt et al., 2007; Mardanova 
et al., 2015), the surface of virus-like particles (VLPs) (Matic et al., 
2011), and as a fusion peptide on β-glucuronidase (Firsov et al., 
2015) and HA (Stanekova et  al., 2011). De Filette et  al. (2005) 
used hepatitis B virus core protein (HBc) as a carrier, and fused 
M2e to either the C-terminal of HBc or inserted in the immune 
dominant loop of HBc. Immunization of mice with this HBc-M2e 
candidate vaccine resulted in 100% protection against lethal chal-
lenge (Fiers et al., 2004; De Filette et al., 2005, 2008).
Influenza antigens have been successfully produced using 
insect cell expression systems. Baculovirus-expressed influenza 
vaccines can be produced rapidly, which is necessary when taking 
into account that currently circulating strains need to be assessed 
annually. The resultant insect cell-expressed product is consid-
ered to be both safe and of a high standard (Safdar and Cox, 2007; 
Cox, 2008). Producing M2e tetramers in baculovirus insect cell 
expression systems and accumulating them into nanoclusters 
results in increased humoral and cellular immunogenicity (Wang 
et al., 2014).
As an alternative approach, numerous researchers have suc-
cessfully produced influenza antigens in tobacco plants – and in 
particular HA (D’Aoust et al., 2008; Shoji et al., 2008; Mortimer 
et al., 2012). Plant expression systems are advantageous due to 
their ability to carry out post-translational modifications similar 
to other eukaryotes, and in rapidly producing large quantities of 
antigen. This system is more economical since plants do not need 
expensive material for growth and maintenance, and it reduces 
concerns over human pathogens contaminating vaccine prepara-
tions (Nemchinov and Natilla, 2007; Gomez et al., 2009; Rybicki, 
2009). Nemchinov and Natilla (2007) developed a candidate 
plant-based universal influenza vaccine by displaying the M2e 
epitope on the capsid protein (CP) of cucumber mosaic virus 
Ixora strain (CMV-Ix) in a potato virus X (PVX)-based vector. 
The resulting plant-based chimeric CMV capsids reacted specifi-
cally to antibodies raised against the synthetic M2e, indicating the 
potential of this system.
This study forms part of an ongoing initiative to investigate 
and establish a rapid-response vaccine production platform to 
deal with future influenza pandemics in South Africa. The highly 
pathogenic H5N1 influenza A virus, with a mortality rate of up 
to 60% in humans (http://www.who.int/), was chosen for this 
purpose. To date, human-to-human transmissions are limited 
but the likelihood of H5N1 mutating into a strain that facilitates 
transfer necessitates efficient pandemic vaccination preparedness 
strategies and awareness (Webster and Govorkova, 2006; Imai 
et al., 2013; Kaplan and Webby, 2013). To date, potential plant-
produced subunit HA vaccines (Mortimer et al., 2012) as well as 
HA DNA vaccine candidates (Mortimer et al., 2013) have been 
created as part of this South African initiative.
Fusion of small or soluble proteins to a signal sequence that 
drives the assembly and sequestration of the protein bodies (PBs) 
(Torrent et al., 2009) can significantly increase the immunogenic-
ity of the protein. Accordingly, for this study, we investigated the 
fusion of a consensus M2e sequence to a signal tag (Zera®, ERA 
Biotech) that targets the recombinant protein to form PBs. This 
tag has previously been shown to dramatically improve yields of 
non-structural papillomavirus protein (E7SH) in plants as well 
as to have adjuvant properties (Whitehead et  al., 2014). Zera® 
had adjuvant activity, whether fused to E7SH or simply added 
to it, which could be highly advantageous in a vaccine candidate. 
The N-terminal proline-rich domain of maize γ-zein (Zera® tag) 
is characterized by 4 domains: these are a 19 amino acid signal 
peptide, a repeat domain containing 8 repeats of the sequence 
PPPVHL, a Pro-X domain including numerous proline residues 
as well as a hydrophobic cysteine rich C-terminal domain, and 
lastly, a sequence that retains it in the endoplasmic reticulum 
(ER). This allows for the formation of membrane-bound PBs, 
thereby protecting the recombinant protein from proteolytic 
degradation inside the host cells, and concentrating and seques-
tering the recombinant protein. PBs are easily concentrated and 
partially purified by simple centrifugation, and the polypeptide is 
generally water soluble in the presence of reducing agents, which 
greatly facilitates and simplifies recombinant protein purification 
(Torrent et al., 2009).
For this study, we determined the feasibility of creating an 
immunogenic M2e candidate vaccine by transiently expressing 
Zera®M2e PBs in tobacco plants and in insect cells. The protein 
expressed by recombinant baculovirus cells Sf21 was used as an 
experimental control reagent. M2e was fused to Zera® to enable 
protein purification and to increase the immunogenicity of the 
protein (Torrent et  al., 2009; Whitehead et  al., 2014). Codon 
optimization has been widely used to enhance protein expres-
sion in heterologous systems (Gouy and Gautier, 1982). The 
Zera®M2e gene was codon optimized for this study such that it 
either displayed characteristics of abundantly expressed plant 
genes (Nicotiana benthamiana codon optimized) or human 
genes (human-codon optimized), as we have found it necessary 
to empirically determine codon preferences in other studies 
(Maclean et al., 2007). Immunogenicity of the PBs isolated from 
FigUre 1 | avian and human influenza a h5n1 virus M2e sequences retrieved from genBank and aligned using clustal X. EU590690 turkey, EU590684 
houbara bustard, EU263984 human, and EU146698 human. The 23 amino acid ectodomain is indicated by the red square. Differences in the amino acid sequence 
are indicated in different colors.
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plants was established by immunization of mice, and analysis of 
the immune sera for the presence of antibodies against M2e.
MaTerials anD MeThODs
identification and synthesis of Zera®M2e 
Peptide
Multiple avian and human influenza A H5N1 virus M2e 
sequences were retrieved from GenBank and aligned using 
Clustal X (Larkin et al., 2007). From these, four sequences were 
selected (EU590690, EU590684, EU146698, and EU263984) to 
create a consensus sequence, SLLTEVETPTRNEWECRCSDSSD, 
which corresponded exactly to the EU263984 sequence [A/
human/China/GD02/2006(H5N1)] (Figure  1). To create 
the Zera®M2e sequence, the Zera® sequence (ERA Biotech), 
including an enterokinase cleavage site (DDDDK) (Whitehead 
et al., 2014), was synthesized and inserted upstream of the M2e 
consensus sequence. The Zera®M2e nucleotide sequence was 
both plant- and human-codon optimized, and synthesized by 
GeneArt (Germany).
construction Plant recombinant Vector
For plant expression, both plant- and human-codon optimized 
Zera®M2e were cloned into the plant expression vector pTRAc 
(GenBank ID: AY027531) using AflIII and XhoI restriction 
enzyme sites (pTRAc-Zera®M2e). The pTRAc vector allows 
protein expression in the cytoplasm (Maclean et  al., 2007), 
with subsequent targeting to the ER by the Zera® sequence. The 
plasmids were transformed into E. coli DH5α and recombinant 
bacterial colonies were confirmed by PCR using Zera®M2e 
primers (Fw: 5′-ATGCGGGTGCTGCTGGTC-3′ and Rev: 
5′-TGGGTGTCTCCACCTCGGTC-3′). The integrity of the 
plasmids was confirmed by restriction digest mapping with 
XhoI and AflIII restriction enzymes as well as sequencing. The 
pTRAc-Zera®M2e plasmids were subsequently transformed into 
Agrobacterium tumefaciens GV3101 via electroporation (Maclean 
et al., 2007).
expression and Purification of Zera®M2e 
in Nicotiana benthamiana
Agrobacterium tumefaciens-mediated transient expression in N. 
benthamiana plants was performed according to Mortimer et al. 
(2012). In short, recombinant plant- and human-codon opti-
mized pTRAc-Zera®M2e plasmids were vacuum infiltrated into 
6-week-old plants, with co-infiltration of A. tumefaciens LBA4404 
(pBIN-NSs) containing the NSs gene silencing suppressor of 
tomato-spotted wilt virus (TSWV) (Marcel Prins, Laboratory 
of Virology, Wageningen, The Netherlands); this enhances gene 
expression by suppressing post-translational gene silencing 
(Takeda et al., 2002).
Infiltrated plant tissue was harvested 8 days post infiltration 
(dpi), followed by grinding in liquid nitrogen with a mortar and 
pestle, after which the extract was homogenized in the Zera® 
extraction buffer [100 mM Tris (pH 8), 0.5M NaCl, 50 mM MgCl2, 
and 10 mM EDTA]. The homogenate was filtered through two 
layers of Miracloth (Merck) and purified by ultracentrifugation 
(Beckman SW32Ti rotor) at 21,600 × g for 2 h through a 60% 
sucrose cushion.
Protein expression was assessed by western blot analysis, with 
proteins resolved on 15% SDS-PAGE gels. The primary antibody, 
rabbit anti-Zera® polyclonal antibody (provided by ERA Biotech, 
Spain), was used at a dilution of 1:7000 together with a secondary 
goat anti-rabbit antibody (Sigma, Steinheim, Germany) at 1:7000 
dilution. Nitro blue tetrazolium chloride/5-bromo-4 chloro-
3-indolyl phosphate (NBT/BCIP) phosphate substrate (KPL, 
Gaithersburg, MD, USA) was used for detection. Plant-produced 
Zera®M2e was quantified by comparing band intensities of the 
Zera®M2e to known bovine serum albumin (BSA) concentra-
tions by gel densitometry (Gene Genius Bioediting system, 
Syngene).
construction and expression of Zera®M2e 
in insect cells
For insect cell expression, plant- and human-codon opti-
mized Zera®M2e was cloned into the pFastBac Dual vector 
(InVitrogen, Carlsbad, CA, USA) between the polyhedrin 
(PPH) promoter and Tn7L terminator using EcoRI and PstI 
restriction sites, resulting in pFastBac-Zera®M2e. Recombinant 
plasmids screened by PCR with pFastBac primers (Fw: 
5′-GATGGTGGGACGGTATGAATAATCC-3′ and Rev: 
5′-GGTATTGTCTCCTTCCGTGTTTGA-3′). The integrity of 
the plasmids was confirmed by plasmid mapping with EcoRI and 
PstI restriction enzymes and sequencing. Recombinant bacmid 
DNA was obtained by transposition of pFastBac-Zera®M2e into 
E. coli DH10Bac according to the manufactures instructions 
(InVitrogen, Carlsbad, CA, USA).
Recombinant baculoviruses (rBV) Sf 21 cells containing plant- 
and human-codon optimized Zera®M2e were generated, and 
plaque assays to determine rBV titers were performed according 
to the Bac-to-Bac© baculovirus expression system manufacturer’s 
protocols (InVitrogen, Carlsbad, CA, USA). TC Plates were stained 
with 1 g/ml neutral red solution (Sigma, Steinheim, Germany) to 
FigUre 2 | Western blots of human- and plant-codon optimized 
recombinant Zera®M2e protein bodies (PBs). Protein expression was 
detected with anti-Zera® antibody and goat anti-rabbit antibody. (a) Transient 
expression in N. benthamiana. Plants were harvested 8 days post infiltration. 
Lane 1 contained PageRuler™ Prestained protein ladder (Fermentas), lane 2 
contained the Zera®M2e plant-codon optimized protein, lane 3 contained the 
Zera®M2e human-codon optimized, and lane 4 contained non-infiltrated 
control plant. (B) Expression of recombinant baculovirus in Sf21 insect cells, 
72 h post infection (hpi), using the Bac-to-Bac© baculovirus expression 
system. Lane 1 contained the PageRuler™ Prestained protein ladder 
(Fermentas), lane 2 contained the recombinant human-codon-optimized 
Zera®M2e PB, lane 3 is the recombinant plant-codon-optimized Zera®M2e, 
and lane 4 contained the negative cell lysate transfection control.
December 2015 | Volume 3 | Article 1974
Mbewana et al. H5N1 Zera®M2e Produced in Plants
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org
visualize individual plaques. Protein expression and purification 
analysis are as described for the plant-produced proteins.
animal Trials and serum analysis
Only the plant-produced Zera®M2e PB yields were judged to 
be sufficient for animal trials. Accordingly, 20 female Balb/c 
mice (7  weeks old) were divided into two groups: (a) plant-
produced Zera®M2e PB and (b) PBS negative control group. A 
dose of 4.5 μg Zera®M2e PB was administered intramuscularly 
(I.M.) to mice, into each anterior tibialis muscle. Four doses 
were administered at 2-week intervals on days 0, 14, 28, and 
31. Pre-vaccination serum was collected 3  days prior to vac-
cination. Following vaccination, sera were collected before each 
boost (on days 14, 28, and 31), and stored at −20°C until for 
further analysis. Eleven days after the final dose, animals were 
euthanized (day 42). The animal experiments were approved by 
the University of Cape Town’s (UCT) Animal Ethics Committee 
(HSFAEC 009/001).
Western blots were performed to determine the presence 
of Zera®M2e-specific antibodies in the mouse sera. Our insect 
cell- and plant-produced Zera®M2e PB samples were resolved 
separately on 15% SDS-PAGE gels, followed by transfer onto a 
nylon membrane (Armersham, Bioscience, UK) by semi-dry 
blotting (BioRad Hercules, CA, USA). The membranes were cut 
into individual strips and were incubated in 1:5000 dilutions of 
serum from mice injected with pTRAc-Zera®M2e PB and PBS, 
respectively. The secondary goat anti-mouse antibody (Sigma, 
Steinheim, Germany) was used at 1:7000 dilutions. As a positive 
control, the commercial rabbit polyclonal anti-M2 antibody 
(ab65086) (Abcam, Cambridge, UK) was used at a 1:5000 dilution 
followed by the secondary goat anti-rabbit antibody (Sigma), at 
a 1: 7000 dilution.
To assess if the sera did not only bind the Zera® but also the 
M2e, western blots were performed with a construct encoding 
multiple M2e (5xM2e) fused with the avian influenza H5N1 (A/
Vietnam/1194/2004 H5N1) transmembrane and cytosolic tail 
(5xM2e_tHA). Crude plant extract containing the 5xM2e_tHA 
protein was resolved on 12% SDS-PAGE gels, and the protein was 
probed on blots with a 1:100 sera dilution. As a positive control, 
5xM2e_tHA was probed with 1:5000 anti-M2 monoclonal anti-
body (14C2). Alkaline phosphate-conjugated goat anti-mouse 
IgG was used as a secondary antibody at a 1:10,000 dilution.
resUlTs
expression of recombinant Protein in  
N. benthamiana
Gene-codon optimization has been shown to significantly 
enhance gene expression in plants, and especially if the genes 
have a high GC content. The Zera®M2e gene was plant- and 
human-codon optimized and successfully cloned into plant 
expression vector pTRAc. Protein expression analysis revealed 
that both plant- and human-codon optimized Zera®M2e PB were 
successfully expressed in N. benthamiana 8 dpi. In western blots, 
an expected band of 17 kDa corresponding to the M2e epitope 
fused with Zera® tag was observed. There were no differences 
in the expression levels between the plant- and human-codon 
optimized Zera®M2e, indicating that codon optimization did not 
influence gene translation and expression in the plant expression 
system (Figure 2A).
expression of recombinant Protein in 
insect cells
For insect cell expression, plant- and human-codon optimized 
Zera®M2e were successfully cloned into pFastBac Dual vector 
under the control of the pH10 promoter and expressed in Sf21 
insect cells 72 h post infection (hpi) (Figure 2B). The plant-codon 
optimized gene expression was weak as assessed by western blot 
compared to the human-codon optimized gene. In this case, 
human-codon usage was more favorable for the insect cell expres-
sion system.
Purification of recombinant Protein
The PBs can be easily purified by centrifugation through a sucrose 
cushion (Torrent et  al., 2009). Ultracentrifugal concentration 
through a sucrose cushion showed that the Zera®M2e PBs formed 
insoluble pellets. The pelleted insect cell-produced Zera®M2e was 
detectable on western blots but was undetectable on Coomassie-
stained SDS-PAGE gels, indicating low protein concentra-
tion. The concentrated and partially purified plant-produced 
Zera®M2e PB was visible on Coomassie-stained SDS-PAGE gels 
and was quantified by comparing it to known BSA concentra-
tions run on stained gels (Figure 3). Bands corresponding to the 
monomeric (17 kDa), dimeric (34 kDa), and tetrameric (51 kDa) 
forms of the Zera®M2e PB were observed (Figure 3). Only the 
band corresponding to the putative monomeric form was used 
for quantitation, to give estimated expression levels ranging from 
125 to 205 mg Zera®M2e PB/kg fresh weight (FW) as measured 
FigUre 3 | Quantification of Zera®M2e produced in plants. Bovine 
serum albumin (BSA) was used as a standard. Lane 1 and 7 contained 
PageRuler™ Prestained protein ladder (Fermentas), lane 2 contained 
6.26 mg/ml, lane 3 contained 3.13 mg/ml, lane 4 contained 1.56 mg/ml, and 
lane 5 contained partially purified Zera®M2e plant-codon optimized protein. 
While lane 6 is a western blot containing the partially purified Zera®M2e 
plant-codon optimized protein detected with anti-Zera®antibody.
FigUre 4 | Detection of Zera®M2e-specific antibodies in plant-
produced Zera®M2e immunized mice sera. Insect cell-produced 
Zera®M2e protein bodies (PBs) were loaded in each lane, and then the 
membrane was cut into strips and probed with individual mouse serum. Lane 
1 contains PageRuler™ Prestained protein ladder (Fermentas), lane 2 
contains the positive control, i.e., Zera®M2e PB detected with a commercial 
M2 primary antibody (1:5000) (ab65086, Abcam, Cambridge, UK). Lane 3–6 
were detected with mice sera from mice immunized with plant-produced 
Zera®M2e PB (1:5000) and Lane 7 contains negative control sera: mice 
immunized with PBS.
FigUre 5 | confirmation of specificity of the Zera®M2e mice sera 
against the fused M2e plant-produced protein. Equal volume of 
plant-produced 5xM2e_tHA proteins were loaded in each lane. The 
membranes were cut in the middle and each half was probed either with the 
commercial M2 antibody or mice serum from mice immunized with 
plant-produced Zera®M2e PB. Lanes 1 and 5 contain Agrobacterium-
infiltrated crude plant extract (negative control), Lanes 2 and 4 contain the 
5xM2e_tHA plant crude extract, and Lane 3 contains PageRuler™ 
Prestained protein ladder (Fermentas). Lanes 1 and 2 were detected with 
commercial M2 (14C2) primary antibody (1:5000). Lanes 4 and 5 were 
detected with mice sera from mice immunized with plant-produced 
Zera®M2e PB (1:100).
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by densitometry. The higher yielding plant-produced Zera®M2e 
PB was used for animal trials.
animal serum analysis
Ten mice were immunized with the plant-produced Zera®M2e 
PB. No clinical manifestation was observed after the injection of 
the PBs in any of the mice. After the fourth immunization, the 
sera were analyzed for the presence of Zera®M2e-specific anti-
bodies. Western blots indicated that the immune sera successfully 
reacted with the plant-produced Zera®M2e PB at a dilution of 
1:5000, indicating a high Zera®M2e-specific antibody titer. Sera 
from PBS-inoculated control mice did not bind Zera®M2e PB 
(Figure S1 in Supplementary Material).
When the mouse sera were tested with our plant-produced 
Zera®M2e PB, a high level of background was observed on the 
western blots even when the sera were diluted 1:40,000, which 
made it difficult to identify the expected band sizes (Figure S1 in 
Supplementary Material). This is because our candidate vaccine 
was produced in plants, and therefore the sera also reacted with 
high specificity to plant proteins contaminating the preparations. 
In an attempt to lower the background for more accurate results, 
the sera were then analyzed using our insect cell-produced 
Zera®M2e PB (Figure  4). The immune sera reacted far more 
specifically, with a distinct band corresponding to the monomeric 
Zera®M2e PB.
To be certain whether the mouse sera produced reacted spe-
cifically with the M2e peptide, the sera were tested by western 
blot against the plant-produced 5xM2e_tHA, which contains 
no Zera® sequence (Figure 5). The serum strongly reacted with 
the 35-kDa multiple protein dimer and a 70-kDa trimeric form, 
affirming that indeed the mouse sera did not only have antibodies 
against Zera® peptide but also against the M2e sequence.
DiscUssiOn
In this study, we attempted to overcome the limitations of the 
current influenza vaccines with regards to antigenic shift and drift 
associated with HA and NA (Webster et al., 1992), by focusing on 
the influenza A virus M2e peptide as a universal vaccine candi-
date, due to its high degree of conservation since the emergence 
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of the highly virulent Spanish flu pandemic strain of 1918 (Fiers 
et  al., 2004). Generally, M2e vaccine candidates are produced 
either as chemically conjugated molecules or by genetic fusion to 
a variety of carrier proteins, such as virion- or VLP-forming pro-
teins (Mozdzanowska et al., 2003; Ionescu et al., 2006; Tompkins 
et al., 2007; Denis et al., 2008; Matic et al., 2011; Stanekova et al., 
2011; Ravin et al., 2012). In our study, we fused the M2e with a 
self-aggregating signal tag, Zera®. The Zera® fusion tag has the 
ability to segregate the protein from the plant secretory pathway 
into membrane-delimited organelles in the ER: the retention and 
the self-assembly of γ-zein lead to PB formation, stabilizing the 
protein inside vesicles formed by invagination of the ER lumen 
(Mainieri et  al., 2004; Torrent et  al., 2009). This is known to 
facilitate protein purification, as shown by the result of ultracen-
trifugation of the plant-produced Zera®M2e PBs through a 60% 
sucrose cushion: PBs were concentrated in the pellet fraction, 
with very little soluble protein present.
As the 2009 H1N1 “swine flu” pandemic illustrated, South 
Africa will have to rely on developed countries for vaccine sup-
plies during an outbreak (Mortimer et al., 2012, 2013). We are 
therefore systematically investigating the feasibility of establish-
ing rapid-response platforms to produce influenza virus vaccine 
candidates in South Africa, by implementing novel strategies that 
are both cost-effective and can be more readily up-scaled than 
traditional egg-based vaccines (Mortimer et al., 2012).
In the present work, we were able to express Zera®M2e in both 
plants and insect cells. The protein was expressed as monomers, 
dimers, and tetramers. This is in line with previous work, where 
M2e was expressed in baculovirus expression system (Holsinger 
and Lamb, 1991; Sugrue and Hay, 1991). In plants, we achieved a 
yield of 125–205 mg/kg FW for the Zera®M2e. These are gener-
ally higher yields than those that have been achieved by other 
researchers. Nemchinov and Natilla (2007) previously reported 
yields of avian influenza A CMV-M2e fusion protein expression 
in N. benthamiana of 6–8 mg/kg leaf tissue. Matic et al. (2011) 
expressed influenza M2e epitopes on chimeric HPV VLPs in 
plants and obtained 78–120 mg/kg plant material. Most recently, 
Firsov et al. (2015) expressed M2e fused with β-glucuronidase in 
transgenic duckweed, and obtained yields from 90 to 970 mg/kg 
plant FW.
When the serum from mice vaccinated with plant-produced 
Zera®M2e PB was used to detect the same protein produced 
in insect cells on western blots, the serum specifically detected 
only the Zera®M2e protein (Figure 4), indicating that the plant-
produced antigen was immunogenic. Use of the plant-produced 
protein, however, showed that the sera also reacted with other 
plant proteins that co-purified with the Zera®M2e PBs. Zera® 
fusions are known to form large polymers that are resistant to 
degradation (Torrent et  al., 2009). The contaminating proteins 
could include chloroplastic, ribosomal, cytoplasmic, cytoskeleton, 
and mitochondrial plant proteins (Joseph et al., 2012). It is clear 
that using a different expression system for antibody detection 
from that which was used for the antigen production, allowed 
for more efficient and clear detection of the protein. Future work 
will include ultracentrifugation on a sucrose density step gradient 
(Whitehead et al., 2014) to remove unwanted plant protein: this 
should then lead to more specific immune responses only to the 
Zera®M2e PB, with reduced reaction against other plant proteins. 
Testing the Zera®M2e antigen for protection against multiple 
strains of influenza would be advantageous but was not possible 
in this investigation.
While we successfully produced Zera®M2e PB in insect 
cells in this work, and this was valuable as a reagent, our plant-
produced Zera®M2e PB had by far the highest yield, with the 
different soluble forms (monomeric, dimeric, trimeric, and 
tetrameric) probably contributing significantly to the immu-
nogenicity of the candidate vaccine. Bands corresponding to 
the monomeric, dimeric, and tetrameric forms have also been 
detected in previous M2e studies (Holsinger and Lamb, 1991; 
Sugrue and Hay, 1991).
The production of M2e as a fusion product in plants is not new; 
Nemchinov and Natilla (2007) expressed M2e in N. benthamiana 
via a plant viral vector as an internal fusion in the CP of Cucumber 
mosaic virus; Ravin et al. (2012) used a similar vector to express 
M2e fused to the HBc and showed protection against lethal 
challenge in mice. Matic et al. (2011) used the pEAQ-HT vector 
to transiently express M2e and a shortened version (M2e2–9) as 
fusions to HPV-16 L1 protein; the longer peptide was presented 
on capsomers and VLPs, and reacted with anti-M2e antibodies. 
Petukhova et al. (2013) produced recombinant tobacco mosaic 
virus particles presenting M2e on their surfaces and showed these 
were highly immunogenic and protective.
However, our use of the Zera® peptide is novel – moreover, the 
high yield and the immunogenicity of the product, coupled with 
what is almost certainly a far easier purification protocol than 
for any of the fusions detailed above, make it a valuable addition 
to our rapid-response armory against pandemic influenza. Our 
work is therefore further proof that plants are a viable vehicle for 
high-level expression of a peptide vaccine known to elicit broad-
spectrum protection against influenza A viruses.
To conclude, we successfully expressed Zera®M2e PB in both 
insect cell and plant expression systems. Our plant-produced 
Zera®M2e elicited M2e-specific antibodies in mice, which 
indicates that it has potential as a candidate universal influenza 
vaccine. Future work will look at determining the efficacy of these 
antibodies and their potential of broad-spectrum protection 
against influenza strains.
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